Phase 3 in obesity without diabetes
In a 76-week, double-blind, placebo-controlled phase 3 trial of 725 adults with obesity and no diabetes (SYNCHRONIZE-1), both survodutide groups lost more weight than placebo: about 12% and 13% of body weight versus about 5% (treatment-regimen estimand). At least 5% weight loss was reached by about 72% of each survodutide group versus 46% on placebo.
- Study type
- Human trial
- Population
- 725 adults with obesity (BMI 30 or above, or 27 or above with a weight-related complication), without diabetes; phase 3, multicentre, double-blind, placebo-controlled, 76 weeks, with lifestyle counselling in all groups.
- Source
- 1 le Roux et al., 2026
Limitation: Sponsor-funded (Boehringer Ingelheim).
Limitations in full
Sponsor-funded (Boehringer Ingelheim). The abstract reports only the treatment-regimen estimand. Weight loss is an average; individual results varied. Full text not read.